Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
1. CODX withdrew its FDA 510(k) application due to shelf‐life stability concerns. 2. An enhanced COVID-19 test version will be submitted after additional clinical data is collected. 3. The new submission incorporates updated PCR platform developments for improved manufacturing. 4. Premarket price down 14.9%, indicating immediate investor concerns.